In the first call of Valorisation Programme of NanoNextNL (May 2015) the following business case was awarded:
Nanomedicine clearing agent
Tagworks Pharmaceuticals is a participant in the NanoNextNL Valorisation Programme with 2 business cases and secured a total of € 325k in business financing. Tagworks is working on antibody drug conjugate (ADC) technology by applying ‘click’ chemistry to activate ADCs on the tumour. They are also working on a novel liver-targeted clearing agent. Through a chemical reaction, this agent enables instantaneous clearance of tagged nanomedicine from the blood at any desired time boosting the therapeutic window of ADCs or drug containing liposomes by controlling and minimising off-target toxicity.
NanoNextNL highlight Tagworks Pharmaceuticals: Label on cancer cell for targeted treatment